ANDREW H LIMPER, M.D.
Osteopathic Medicine at 1 St, Rochester, MN
License number
Minnesota 29373
Category
Osteopathic Medicine
Type
Pulmonary Disease
Address
Address
200 1St St SW, Rochester, MN 55905
Phone
(507) 284-2511
Organization information
See more information about ANDREW H LIMPER at bizstanding.comMayo Clinic - Andrew H Limper MD
200 1 St SW #W4, Rochester, MN 55905
Categories:
Physicians & Surgeons
Phone:
(507) 284-2511 (Phone)
Professional information
Andrew H Limper, Rochester MN
Specialties:
Pulmonologist
Address:
200 1St St Sw, Rochester, MN 55905
Education:
University of Illinois, College of Medicine - Doctor of Medicine*
The Mayo Clinic - Residency - Internal Medicine*
The Mayo Clinic - Residency - Internal Medicine*
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine*, American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine)*
Dr. Andrew H Limper, Rochester MN - MD (Doctor of Medicine)
Specialties:
Pulmonology
Address:
Mayo Clinic
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
Certifications:
Internal Medicine, 1987, Pulmonary Disease, 2000
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Mayo Clinic
200 1St St SW, Rochester 55905
Park Nicollet Methodist Hospital
6500 Excelsior Blvd, Saint Louis Park 55426
200 1St St SW, Rochester 55905
Park Nicollet Methodist Hospital
6500 Excelsior Blvd, Saint Louis Park 55426
Education:
Medical School
University Of Illinois College Of Medicine Chicago
Graduated: 1984
Mayo Grad School Med
Graduated: 1986
Graduated: 1991
University Of Illinois College Of Medicine Chicago
Graduated: 1984
Mayo Grad School Med
Graduated: 1986
Graduated: 1991
Andrew Harold Limper, Rochester MN
Specialties:
Internal Medicine, Pulmonary Disease, Critical Care Medicine
Work:
Mayo Medical School
200 1St St Sw, Rochester, MN 55905
200 1St St Sw, Rochester, MN 55905
Education:
University of Illinois at Chicago (1984)
Cdc2 Protein Kinase From Pneumocystis Carinii
US Patent:
6015700, Jan 18, 2000
Filed:
Jun 8, 1998
Appl. No.:
9/093522
Inventors:
Andrew H. Limper - Rochester MN
Edward B. Leof - Rochester MN
Charles F. Thomas - Rochester MN
Michael P. Gustafson - Rochester MN
Edward B. Leof - Rochester MN
Charles F. Thomas - Rochester MN
Michael P. Gustafson - Rochester MN
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
C12N 900, C12P 2106, C07H 1700
US Classification:
435183
Abstract:
A nucleic acid and corresponding polypeptide that aids in the regulation of the cell cycle in Pneumocystis carinii is described. Antibodies generated against a unique carboxyl-terminus region of the polypeptide have specific binding affinity for P. carinii Cdc2 polypeptide and are benificial in diagnosing and monitoring P. carinii infection in patients. Expression of P. carinii Cdc2 polypeptide in cdc2-mutant yeast and other cdc2-mutant organisms provides a for model for studying the life cycle of P. carinii and for identifying novel therapeutics.
Method For Identifying Inhibitors Of Cdc2 Protein Kinase From Pneumocystis Carinii
US Patent:
5863741, Jan 26, 1999
Filed:
Jun 13, 1997
Appl. No.:
8/874347
Inventors:
Andrew H. Limper - Rochester MN
Edward B. Leof - Rochester MN
Charles F. Thomas - Rochester MN
Michael P. Gustafson - Rochester MN
Edward B. Leof - Rochester MN
Charles F. Thomas - Rochester MN
Michael P. Gustafson - Rochester MN
Assignee:
Mayo Foundation for Medical Education and Research - Rochester MN
International Classification:
C12Q 100, G01N 3353, C12N 912, C12N 900
US Classification:
435 76
Abstract:
A nucleic acid and corresponding polypeptide that aids in the regulation of the cell cycle in Pneumocystis carinii is described. Antibodies generated against a unique carboxyl-terminus region of the polypeptide have specific binding affinity for P. carinii Cdc2 polypeptide and are beneficial in diagnosing and monitoring P. carinii infection in patients. Expression of P. carinii Cdc2 polypeptide in cdc2-mutant yeast and other cdc2-mutant organisms provides a useful model for studying the life cycle of P. carinii and for identifying novel therapeutics.